Header

UZH-Logo

Maintenance Infos

Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry


Fellrath, Jean-Marc; Scherer, Thomas; Franzen, Daniel P; Lovis, Alban; von Garnier, Christophe; Plojoux, Jérôme; Soccal, Paola M (2018). Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry. Journal of Thoracic Disease, 10(S23):S2711-S2718.

Abstract

Background: Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice. Methods: The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment. Results: patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (−0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (−4 points) 87%; 6MWD (+26 m) 60%. Conclusions: Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome Keywords: Chronic obstructive pulmonary disease (COPD); emphysema; bronchoscopic lung volume reduction; coils; registry

Abstract

Background: Endobronchial coils have been demonstrated in three randomized, controlled trials to improve quality of life, exercise tolerance, and lung function in patients with severe emphysema. This therapy is CE-marked and commercially available in Switzerland. Coil treated patients are followed in a post-market Swiss registry to collect safety and effectiveness data in routine clinical practice. Methods: The Swiss coil registry was initiated in October 2013. At the end of November 2016, an interim analysis of all 64 patients treated in five centers was performed to evaluate safety and effectiveness at six months post treatment. Results: patients had completed bilateral treatment with 6-month follow up at the time of data analysis. Patients had very severe, symptomatic emphysema and hyperinflation [38% male, mean age 66 years, BMI 24, FEV1 30% pred., residual volume (RV) 247% pred., 6-minute walking distance (6-MWD) 272 m, St. George Respiratory Questionnaire (SGRQ) 57 points]. Up to 6 months following treatment, seven serious adverse events (SAE) were reported in 6/29 patients. No device removals were necessary. At 6 months, responder rates [% achieving the minimal clinically important difference (MCID)] were as follows: RV (−0.35 L) 76%; FEV1 (+10%) 57%; SGRQ (−4 points) 87%; 6MWD (+26 m) 60%. Conclusions: Endobronchial coil therapy performed in expert centers in Switzerland yields high 6-month responder rates across all relevant outcome Keywords: Chronic obstructive pulmonary disease (COPD); emphysema; bronchoscopic lung volume reduction; coils; registry

Statistics

Citations

Altmetrics

Downloads

15 downloads since deposited on 03 Jan 2019
9 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Pneumology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Pulmonary and Respiratory Medicine
Uncontrolled Keywords:Pulmonary and Respiratory Medicine
Language:English
Date:1 August 2018
Deposited On:03 Jan 2019 13:23
Last Modified:29 Jul 2020 08:50
Publisher:AME Publishing Company
ISSN:2072-1439
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.21037/jtd.2018.04.53
PubMed ID:30210823

Download

Green Open Access

Download PDF  'Endobronchial coil therapy in severe emphysema: 6-month outcomes from a Swiss National Registry'.
Preview
Content: Published Version
Filetype: PDF
Size: 213kB
View at publisher